Orchid Pharma Limited ORCHPHARMA NSEPHARMA
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Trading at a high P/E of 196.2.
- Earnings shrank at -23.7% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 78 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORCHPHARMA Orchid Pharma Limited NSEPHARMA | 792.50 | 196.16 | ₹4,019.49 Cr | - | 2.10% | - | 6.81% | -23.73% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 217.34 Cr | 237.48 Cr | 172.93 Cr | 193.52 Cr | 207.27 Cr | 237.61 Cr |
| Cost of Revenue | - | 124.79 Cr | 138.02 Cr | 98.87 Cr | 132.51 Cr | 143.15 Cr | 151.36 Cr |
| Gross Profit | - | 92.55 Cr | 99.46 Cr | 74.06 Cr | 61.02 Cr | 64.12 Cr | 86.25 Cr |
| Operating Expenses | - | 30.66 Cr | 31.11 Cr | 68.54 Cr | 71.39 Cr | 33.16 Cr | 29.75 Cr |
| Operating Income | - | 61.89 Cr | 68.35 Cr | 5.52 Cr | -10.38 Cr | 30.96 Cr | 56.50 Cr |
| EBITDA | - | 34.85 Cr | 31.88 Cr | 25.62 Cr | 9.30 Cr | 6.07 L | 34.75 Cr |
| Interest Expense | - | 3.80 Cr | 3.92 Cr | 3.26 Cr | 3.73 Cr | 3.18 Cr | 3.09 Cr |
| Pretax Income | - | 22.45 Cr | 19.09 Cr | 13.71 Cr | -3.33 Cr | -12.15 Cr | 22.79 Cr |
| Tax Provision | - | 0 | -3.94 L | 0 | 0 | 0 | 17,000 |
| Net Income | - | 20.78 Cr | 22.29 Cr | 14.91 Cr | -5.72 Cr | -12.61 Cr | 23.78 Cr |
| Diluted EPS | - | 4.10 | 4.40 | 2.94 | -1.13 | -2.49 | 4.69 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 665.90 Cr | 819.07 Cr | 921.93 Cr | 811.33 Cr |
| Cost of Revenue | - | 397.18 Cr | 498.39 Cr | 544.22 Cr | 525.88 Cr |
| Gross Profit | - | 268.72 Cr | 320.68 Cr | 377.70 Cr | 285.45 Cr |
| Operating Expenses | - | 239.05 Cr | 242.21 Cr | 120.91 Cr | 126.92 Cr |
| Operating Income | - | 29.67 Cr | 78.47 Cr | 256.80 Cr | 158.53 Cr |
| EBITDA | - | 142.26 Cr | 141.54 Cr | 144.65 Cr | 69.73 Cr |
| Interest Expense | - | 32.23 Cr | 16.35 Cr | 14.54 Cr | 13.26 Cr |
| Pretax Income | - | 55.25 Cr | 91.95 Cr | 95.56 Cr | 21.02 Cr |
| Tax Provision | - | 0 | -3.12 Cr | -19.35 L | -19.16 L |
| Net Income | - | 46.32 Cr | 92.17 Cr | 99.66 Cr | 20.55 Cr |
| Diluted EPS | -0.48 | 11.35 | 19.06 | 19.65 | - |
Compounded Sales Growth
| 5 Years: | 6.81% |
| 1 Year: | -1.50% |
Compounded Profit Growth
| 5 Years: | -23.73% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +24.70% |
| 6 Months: | -5.06% |
| 3 Months: | +19.12% |
| 1 Month: | +29.31% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 1,225.21 Cr | 1,553.87 Cr | 1,687.91 Cr | 1,910.91 Cr |
| Current Assets | - | 501.01 Cr | 790.75 Cr | 807.42 Cr | 683.90 Cr |
| Cash & Equivalents | - | 22.60 Cr | 3.60 Cr | 21.11 Cr | 7.01 Cr |
| Inventory | - | 228.74 Cr | 149.36 Cr | 198.18 Cr | 256.41 Cr |
| Receivables | - | 215.19 Cr | 195.55 Cr | 241.83 Cr | 263.87 Cr |
| Total Liabilities | - | 536.56 Cr | 384.41 Cr | 420.63 Cr | 623.13 Cr |
| Current Liabilities | - | 371.89 Cr | 259.97 Cr | 285.57 Cr | 278.97 Cr |
| Long Term Debt | - | 148.84 Cr | 120.43 Cr | 131.64 Cr | 327.73 Cr |
| Total Debt | - | 331.35 Cr | 135.18 Cr | 174.61 Cr | 362.59 Cr |
| Total Equity | - | 688.65 Cr | 1,169.47 Cr | 1,267.29 Cr | 1,287.79 Cr |
| Shares Outstanding | - | 4.08 Cr | 5.07 Cr | 5.07 Cr | 5.07 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 18.34 Cr | 125.99 Cr | 19.22 Cr | 101.20 Cr |
| Investing Cash Flow | - | -31.21 Cr | -312.03 Cr | -26.93 Cr | -285.27 Cr |
| Financing Cash Flow | - | 31.17 Cr | 167.04 Cr | 25.22 Cr | 169.98 Cr |
| Capital Expenditure | - | -84.91 Cr | -64.81 Cr | -150.11 Cr | -383.58 Cr |
| Free Cash Flow | - | -66.58 Cr | 61.18 Cr | -130.89 Cr | -282.39 Cr |
| Net Change in Cash | - | 18.29 Cr | -19.00 Cr | 17.51 Cr | -14.10 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 40.4% | 39.2% | 41.0% | 35.2% |
| Operating Margin % | - | 4.5% | 9.6% | 27.9% | 19.5% |
| Net Margin % | - | 7.0% | 11.3% | 10.8% | 2.5% |
| ROE % | - | 6.7% | 7.9% | 7.9% | 1.6% |
| ROCE % | - | 3.5% | 6.1% | 18.3% | 9.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ORCHPHARMA